$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd

$glmd Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000149315224013203 Filed on April 04, 2024

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.030M	$912.0K	$3.923M
YoY Change	-3.83%	-19.93%	-15.74%
% of Gross Profit
Research & Development	$1.121M	$556.0K	$3.569M
YoY Change	-18.65%	-86.89%	-72.54%
% of Gross Profit
Depreciation & Amortization	$6.000K	$5.000K	$31.00K
YoY Change	-33.33%	-37.5%	-11.43%
% of Gross Profit
Operating Expenses	$2.151M	$1.468M	$7.492M
YoY Change	-12.17%	-72.71%	-57.55%
Operating Profit
YoY Change
Interest Expense	$135.0K	-$5.000K	$591.0K
YoY Change	-171.05%	-116.67%	-406.22%
% of Operating Profit
Other Income/Expense, Net			$100.0K
YoY Change			-146.51%
Pretax Income	-$2.016M	-$1.473M	-$6.912M
YoY Change	-23.61%	-72.47%	-61.31%
Income Tax
% Of Pretax Income
Net Earnings	-$2.016M	-$1.473M	-$6.912M
YoY Change	-23.61%	-72.47%	-61.31%
Net Earnings / Revenue
Basic Earnings Per Share			$2.50
Diluted Earnings Per Share	-$1.41	-$0.24	$2.50
COMMON SHARES
Basic Shares Outstanding	5.045M shares		2.770M shares
Diluted Shares Outstanding			2.770M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.64M	$13.31M	$12.64M
YoY Change	-8.29%	-30.71%	-8.29%
Cash & Equivalents	$2.900M	$1.482M	$2.861M
Short-Term Investments	$9.781M	$11.83M	$9.781M
Other Short-Term Assets	$117.0K	$115.0K	$432.0K
YoY Change	2.63%	0.88%	-46.99%
Inventory
Prepaid Expenses	$315.0K
Receivables	$480.0K	$770.0K
Other Receivables	$480.0K	$0.00
Total Short-Term Assets	$13.24M	$14.20M	$13.24M
YoY Change	-10.09%	-30.67%	-10.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$83.00K	$175.0K	$125.0K
YoY Change	-27.19%	-55.24%	-62.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.265M	$3.265M	$3.265M
YoY Change	117.67%		117.67%
Other Assets
YoY Change
Total Long-Term Assets	$3.390M	$3.440M	$3.390M
YoY Change	84.54%	779.8%	84.54%
TOTAL ASSETS
Total Short-Term Assets	$13.24M	$14.20M	$13.24M
Total Long-Term Assets	$3.390M	$3.440M	$3.390M
Total Assets	$16.63M	$17.64M	$16.63M
YoY Change	0.41%	-15.48%	0.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.879M	$1.474M	$1.879M
YoY Change	-26.6%	-68.96%	-26.6%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.750M	$2.091M	$2.750M
YoY Change	-11.12%	-58.44%	-11.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.750M	$2.091M	$2.750M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities	$2.750M	$2.091M	$2.750M
YoY Change	-12.36%	-59.16%	-12.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$193.0M
YoY Change	3.76%
Common Stock	$209.0K
YoY Change	198.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.88M	$15.55M	$13.88M
YoY Change
Total Liabilities & Shareholders Equity	$16.63M	$17.64M	$16.63M
YoY Change	0.41%	-15.48%	0.41%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$2.016M	-$1.473M	-$6.912M
YoY Change	-23.61%	-72.47%	-61.31%
Depreciation, Depletion And Amortization	$6.000K	$5.000K	$31.00K
YoY Change	-33.33%	-37.5%	-11.43%
Cash From Operating Activities	-$898.0K	-$2.179M	-$6.137M
YoY Change	-77.68%	-30.03%	-66.83%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$2.279M	-$3.539M	$800.0K
YoY Change	15.1%	-169.05%	-95.45%
Cash From Investing Activities	$2.279M	-$3.539M	$800.0K
YoY Change	15.16%	-169.05%	-95.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.185M	$0.00
YoY Change		8735.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	6.185M	$6.185M
YoY Change		8735.71%	8735.71%
NET CHANGE
Cash From Operating Activities	-898.0K	-2.179M	-$6.137M
Cash From Investing Activities	2.279M	-3.539M	$800.0K
Cash From Financing Activities	0.000	6.185M	$6.185M
Net Change In Cash	1.381M	467.0K	$848.0K
YoY Change	-167.53%	-77.56%	-197.7%
FREE CASH FLOW
Cash From Operating Activities	-$898.0K	-$2.179M	-$6.137M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$898.0K	-$2.179M	-$6.137M
YoY Change	-77.69%	-30.03%	-66.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001595353
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures		usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2023	GLMD	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants		usd
CY2022	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits		usd
CY2022	GLMD	Change In Fair Value Convertible Note ChangeInFairValueConvertibleNote		usd
CY2021	GLMD	Change In Fair Value Convertible Note ChangeInFairValueConvertibleNote		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits		usd
CY2022	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits		usd
CY2023	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote		usd
CY2021	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote		usd
CY2022	GLMD	Payments For Proceeds From Investment In Associate PaymentsForProceedsFromInvestmentInAssociate		usd
CY2021	GLMD	Payments For Proceeds From Investment In Associate PaymentsForProceedsFromInvestmentInAssociate		usd
CY2022	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	GLMD	Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	GLMD	Conversion Of Convertible Note Into Investment In Associate ConversionOfConvertibleNoteIntoInvestmentInAssociate		usd
CY2021	GLMD	Conversion Of Convertible Note Into Investment In Associate ConversionOfConvertibleNoteIntoInvestmentInAssociate		usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable		usd
CY2022	GLMD	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2021	GLMD	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36345
CY2023	dei	Entity Registrant Name EntityRegistrantName	GALMED PHARMACEUTICALS LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Abba Hillel Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ramat Gan
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	5250608
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, par value NIS 0.15 per share
CY2023	dei	Trading Symbol TradingSymbol	GLMD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5045324	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1197
CY2023	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co.
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2861000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2016000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	117000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	114000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2253000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7528000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11769000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	480000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	825000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	13239000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14724000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	223000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3265000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3390000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1837000	usd
CY2023Q4	us-gaap	Assets Assets	16629000	usd
CY2022Q4	us-gaap	Assets Assets	16561000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1879000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2560000	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	871000	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	534000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2750000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3094000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	44000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.15
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.15
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5045324	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5045324	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1692342	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1692342	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	209000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	70000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207076000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200138000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-454000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-745000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192952000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186040000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13879000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16629000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16561000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 15 reverse share split
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3569000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12995000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27220000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3923000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4656000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5661000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	7492000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17651000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	32881000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	580000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-215000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	414000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6912000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.50
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.65
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.65
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	19.80
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	19.80
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2769539	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2769539	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1676183	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1676183	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1639843	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1639843	shares
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 15 reverse share split
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6137000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18501000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32892000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6912000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	291000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-574000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-443000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6621000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-18440000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32910000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44153000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1886000	usd
CY2021	GLMD	Issuance Of Ordinary Shares In At The Market At Offering Net Of Issuance Costs IssuanceOfOrdinarySharesInAtTheMarketAtOfferingNetOfIssuanceCosts	8147000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9221000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-443000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30497000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1296000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-574000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2023	GLMD	Warrants Net Of Issuance Costs WarrantsNetOfIssuanceCosts	815000	usd
CY2023	GLMD	Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts	6185000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	892000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	291000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6912000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13879000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13879000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 15 reverse share split
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6912000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	31000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-2000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	121000	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-13000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-523000	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	37000	usd
CY2023	GLMD	Proceeds Finance Lease Interest Expense Income ProceedsFinanceLeaseInterestExpenseIncome	6000	usd
CY2022	GLMD	Proceeds Finance Lease Interest Expense Income ProceedsFinanceLeaseInterestExpenseIncome	-36000	usd
CY2021	GLMD	Proceeds Finance Lease Interest Expense Income ProceedsFinanceLeaseInterestExpenseIncome	6000	usd
CY2023	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits	53000	usd
CY2021	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits	-7000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	892000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1296000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1886000	usd
CY2023	GLMD	Change In Fair Value Convertible Note ChangeInFairValueConvertibleNote	265000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-345000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-300000	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	313000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-681000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2311000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2175000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	468000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-440000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	38000	usd
CY2021	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	1000	usd
CY2023	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	4133000	usd
CY2022	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	2373000	usd
CY2021	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	13569000	usd
CY2022	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote	1500000	usd
CY2023	GLMD	Payments For Proceeds From Investment In Associate PaymentsForProceedsFromInvestmentInAssociate	1500000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	8633000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	21440000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	21243000	usd
CY2023	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	2200000	usd
CY2021	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	-3800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	800000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17563000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11462000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	70000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8147000	usd
CY2023	GLMD	Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts	-6185000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9221000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6185000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17368000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	848000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-868000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4062000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2130000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2998000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7060000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2978000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2130000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2998000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	376000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	297000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	562000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199000	usd
CY2023	GLMD	Conversion Of Convertible Note Into Investment In Associate ConversionOfConvertibleNoteIntoInvestmentInAssociate	1765000	usd
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-07-31
CY2023	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2014-02-02
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2900000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2300000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	7500000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	32400000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	17900000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	6900000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193000000.0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	7982000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zzqlevzFSGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zLy9zFeMBtW3">Use of estimates</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED PHARMACEUTICALS LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Significant Accounting Policies (Cont.)</b></span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zOK8xoVNiqCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_869_zavLyP0HdQY5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of credit risk (Cont.)</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	30000.00	usd
CY2023	GLMD	Monthly Deposits Of Employees Percentage On Monthly Salary MonthlyDepositsOfEmployeesPercentageOnMonthlySalary	0.0833	pure
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	16000	usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	470000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6667	shares
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	7528000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	12514000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	30000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	775000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11769000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	315000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	668000	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	47000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	124000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	118000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	33000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	480000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	825000	usd
CY2023Q4	us-gaap	Area Of Land AreaOfLand	590	sqft
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-03-21
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	44000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	41000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	223000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	216000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.023	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	42000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	41000	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	737000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	737000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	55000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	54000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	75000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	76000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	235000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	235000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1102000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1102000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1019000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	988000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	60000000	usd
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	100000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	571000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	160000	usd
CY2023Q4	GLMD	Shortterm Lease Obligation ShorttermLeaseObligation	41000	usd
CY2022Q4	GLMD	Shortterm Lease Obligation ShorttermLeaseObligation	171000	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	7000	usd
CY2023Q4	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	259000	usd
CY2022Q4	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	196000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	871000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	534000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	2800000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	2800000	usd
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	4100000	usd
CY2023	GLMD	Bank Lien On Marketable Securities BankLienOnMarketableSecurities	117000	usd
CY2021Q2	GLMD	Upfront License Fee UpfrontLicenseFee	100000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	380000000	shares
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6200000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1249	shares
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	62.4
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021	GLMD	Interest Income InterestIncome	-562000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	46.5
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	200000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	42.45
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	10000.00	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2667	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.15
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2023	us-gaap	Other Expenses OtherExpenses	100000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	75000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	75000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.05
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	900000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21654	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000.000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21654	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3569000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12995000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27220000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3923000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4656000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5661000	usd
CY2023	GLMD	Bank Fees BankFees	-11000	usd
CY2022	GLMD	Bank Fees BankFees	-22000	usd
CY2021	GLMD	Bank Fees BankFees	-43000	usd
CY2023	GLMD	Interest Income InterestIncome	-375000	usd
CY2022	GLMD	Interest Income InterestIncome	-297000	usd
CY2023	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	13000	usd
CY2022	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	526000	usd
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	80000	usd
CY2023	GLMD	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-265000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	36000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-36000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	580000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-215000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	414000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	165100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	165100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6912000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17866000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32467000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.12	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.12	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1590000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2144000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3896000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1590000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2144000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3896000	usd

Files In Submission

Name	View Source	Status
0001493152-24-013203-index-headers.html	Edgar Link	pending
0001493152-24-013203-index.html	Edgar Link	pending
0001493152-24-013203.txt	Edgar Link	pending
0001493152-24-013203-xbrl.zip	Edgar Link	pending
ex12-1.htm	Edgar Link	pending
ex12-2.htm	Edgar Link	pending
ex13-1.htm	Edgar Link	pending
ex15-1.htm	Edgar Link	pending
ex2-1.htm	Edgar Link	pending
ex8-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form20-f.htm	Edgar Link	pending
form20-f_001.jpg	Edgar Link	pending
form20-f_002.jpg	Edgar Link	pending
form20-f_003.jpg	Edgar Link	pending
form20-f_004.jpg	Edgar Link	pending
form20-f_005.jpg	Edgar Link	pending
glmd-20231231.xsd	Edgar Link	pending
form20-f_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
glmd-20231231_cal.xml	Edgar Link	unprocessable
glmd-20231231_def.xml	Edgar Link	unprocessable
glmd-20231231_lab.xml	Edgar Link	unprocessable
glmd-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd

2023 Q4 Form 20-F Financial Statement

#000149315224013203 Filed on April 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GLMD Galmed Pharmaceuticals Ltd. Stock $glmd

2023 Q4 Form 20-F Financial Statement

#000149315224013203 Filed on April 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd